SunBio

At a glance

SunBio filed 24 disclosures in the last 12 months, including 8 insider and 1 buyback. The most recent key filing was on Jun 9.

Revenue for 2025 was ₩13.7B, up 57.5% on 2024. Operating margin was 36.8% against -6.1% a year earlier. Debt was 110% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩3.5B and operating profit of ₩741.9M.

The 2025 annual report lists 29 employees with an average tenure of 9.1 years and average pay of ₩51.9M. Its 5 directors and auditors were paid ₩82.6M each on average. It paid no cash dividend for 2025. 노광 and related parties held 31.96% at year end.

From the 2025 annual report

Staff: 29 (18 men, 11 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩1.5B. Directors and auditors: 5, paid ₩413.1M in total.

No cash dividend was paid for 2025.

Largest shareholder

노광 holds 26.07%; with 37 related parties the group holds 31.96% of common shares at year end (from 32.08% at the start of the year).

Auditor: 다산회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary